Dasatinib

From Ganfyd

Jump to: navigation, search

Dasatinib is an ABL tyrosine kinase inhibitor. It has shown promising results in the treatment of chronic myeloid leukaemia (CML) and Ph-positive acute lymphoblastic leukaemia (ALL) that has become resistant to Imatinib[1][2][3].

Side-effects

References